Drugs / SN1011
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04041544 Comparator | Aug 2019 → Jul 2020 | autoimmune disease | SinoMab BioScience Ltd | Unknown | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-09 | SinoMab BioScience Ltd | SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE sinomab.com ↗ |
| 2022-04-20 | SinoMab BioScience Ltd | SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA sinomab.com ↗ |
| 2022-02-07 | SinoMab BioScience Ltd | SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE sinomab.com ↗ |
| 2021-01-15 | SinoMab BioScience Ltd | SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China sinomab.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SN1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041544 ↗ |
| Action | Inhibit | “SN1011 is known as a BTK inhibitor.” NCT04041544 ↗ |
| Route | Oral | “Following Single and Multiple Oral Dose Administration” NCT04041544 ↗ |
| Target | BTK | “SN1011 is known as a BTK inhibitor.” NCT04041544 ↗ |